Steroid avoidance or withdrawal in kidney transplantation

Area of Science:

• Nephrology
• Transplantation Immunology
• Pharmacology

Background:

• Current kidney transplantation guidelines support steroid avoidance or early withdrawal.
• Late steroid withdrawal (after the first posttransplant months) has been recently discouraged by guidelines.
• This review assesses recent data on the tolerability of different steroid-sparing strategies in kidney transplant recipients.

Purpose of the Study:

• To evaluate the tolerability of steroid avoidance and withdrawal in kidney transplantation.
• To analyze recent data on the safety and efficacy of various steroid-sparing protocols.

Main Methods:

• Review of recent scientific literature and clinical data.
• Analysis of outcomes in kidney transplant recipients undergoing different steroid-sparing regimens.
• Assessment of graft function, survival rates, and rejection episodes.

Main Results:

• Steroid avoidance or early withdrawal is associated with increased rates of reversible, mild acute rejection.
• These strategies are well tolerated in low-immunological-risk recipients on specific immunosuppressive regimens (calcineurin inhibitor, mycophenolate mofetil, and induction therapy with anti-IL2 receptor antibodies or thymoglobulin) for up to 5 years.
• Late steroid withdrawal (3-6 months post-transplant) demonstrates stable graft function and survival up to 3 years.
• Observed cardiovascular and other benefits are evident in some studies, but definitive proof from randomized controlled trials is pending.

Conclusions:

• Both early and late steroid withdrawal are safe and well-tolerated in carefully selected low-risk kidney transplant recipients using modern immunosuppression.
• Further randomized controlled trials are necessary to confirm benefits and explore efficacy with novel immunosuppressive combinations (e.g., mTOR inhibitors, belatacept).